We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




LAMP Malaria Test Detects Less-Diagnosed Species

By LabMedica International staff writers
Posted on 16 May 2019
A new loop-mediated isothermal amplification (LAMP) molecular assay has been developed that can detect Plasmodium vivax, a species of the parasite that causes malaria.

Almost all molecular tests currently available detect P. More...
falciparum, in part because it causes the highest mortality of the different species. However, P. vivax is actually more widespread, with more than 2.5 billion people at risk of infection.

The new LAMP assay was evaluated recently in Colombia using a protocol of consecutive testing, a pan-plasmodium LAMP test followed by the P. vivax test, with polymerase chain reaction (PCR)-based testing as the comparator. In all, 365 fingerpick blood samples from patients with fever were evaluated, and the P. vivax test showed a sensitivity of approximately 94% and a specificity of 92%. Importantly, the test also has a low limit of detection of around one to two parasites per microliter of patient sample.

The LAMP assay was developed by Eiken Chemical (Tokyo, Japan) with the collaboration of The Foundation for Innovative New Diagnostics (FIND, Geneva, Switzerland) who coordinated laboratory testing in collaboration with the Hospital for Tropical Diseases (London, UK). FIND has negotiated pricing for the Loopamp tests and HumaTurb system, with a kit of 96 P. vivax tests costing EUR 499.20 (USD 560) and the HumaTurb costing EUR 15,900. There is also a solution for lower-throughput settings called HumaLoop that is a lower cost.

Xavier C. Ding, PhD, the team leader for malaria diagnostics at FIND, said, “It's only recently that there is a recognition that if we are ever to eliminate malaria, we also need some vivax-specific tests, because that species has its own biological specificities and is much more challenging to eliminate that falciparum.” This is because, unlike P. falciparum, P. vivax can lie dormant in the liver of an infected person in a stage called a hypnozoite, and a person with hypnozoites is then prone to relapsing malarial disease. Dr. Ding added, “There is big hope that this will make it easier and more accessible to get treatment for liver-stage parasites, but that also means you also need good diagnostic tools to identify those people who have vivax.”

Related Links:
Eiken Chemical
The Foundation for Innovative New Diagnostics
Hospital for Tropical Diseases


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.